Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (abre una nueva ventana)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Fuente‎: Ann Intern Med 2008;148(12):939-55.

Indexado en‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (abre una nueva ventana)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (abre una nueva ventana)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Fuente‎: Am J Hematol 2000;64(1):26-31.

Indexado en‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (abre una nueva ventana)

Hydroxyurea for the treatment of sickle cell anemia. (abre una nueva ventana)

Platt OS.

Fuente‎: N Engl J Med 2008;358(13):1362-9.

Indexado en‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (abre una nueva ventana)

Clinical effectiveness of decitabine in severe sickle cell disease. (abre una nueva ventana)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Fuente‎: Br J Haematol 2008;141(1):126-9.

Indexado en‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (abre una nueva ventana)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (abre una nueva ventana)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Fuente‎: Blood 2010;115(12):2354-63.

Indexado en‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (abre una nueva ventana)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (abre una nueva ventana)

Hirst C, Owusu-Ofori S.

Fuente‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indexado en‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (abre una nueva ventana)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (abre una nueva ventana)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Fuente‎: Lancet Haematol 2021;8(5):e323-33.

Indexado en‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (abre una nueva ventana)

Sickle cell disease. (abre una nueva ventana)

Meremikwu MM, Okomo U.

Fuente‎: BMJ Clin Evid 2011;02:2402.

Indexado en‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (abre una nueva ventana)

A phase 3 trial of l-glutamine in sickle cell disease. (abre una nueva ventana)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Fuente‎: N Engl J Med 2018;379(3):226-35.

Indexado en‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (abre una nueva ventana)

Malaria chemoprophylaxis in sickle cell disease. (abre una nueva ventana)

Oniyangi O, Omari AA.

Fuente‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indexado en‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (abre una nueva ventana)